BMO Capital Starts bluebird bio (BLUE) at Market Perform

November 10, 2016 4:52 PM EST
Get Alerts BLUE Hot Sheet
Price: $67.60 +4.00%

Rating Summary:
    15 Buy, 3 Hold, 1 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade BLUE Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

BMO Capital initiates coverage on bluebird bio (NASDAQ: BLUE) with a Market Perform rating and a price target of $61.00.

Analyst Matthew Luchini commented, "Our Market Perform rating is based on our belief that while recently presented preclinical Process 2 manufacturing data are encouraging, upside in BLUE is dependent on confirmation that recently implemented protocol amendments (including Process 2) will translate into better clinical outcomes in sickle cell disease and β0/ β0 TDT, which we do not expect until mid-2017 (EHA meeting: June 22-25) at the earliest. We would look to get more constructive on BLUE upon confirmation improved LentiGlobin efficacy in SCD and β0/β0 TDT, something we believe should happen in 2017."

For an analyst ratings summary and ratings history on bluebird bio click here. For more ratings news on bluebird bio click here.

Shares of bluebird bio closed at $52.60 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, New Coverage

Related Entities

BMO Capital

Add Your Comment